期刊文献+

Flt3配体在急性髓系白血病化疗过程中的变化及意义 被引量:6

暂未订购
导出
摘要 目的通过检测FLt3配体(FL)浓度在急性髓系白血病患者化疗前后的变化情况,统计分析其与白细胞数量变化的相关性。方法对48例急性髓系白血病患者进行追踪观察,于化疗前、化疗结束后5~7 d和20~30 d取外周血2,0例健康人为正常对照,应用酶联免疫吸附技术(ELISA),检测FL在白血病初治和缓解患者化疗前后浓度的动态变化。结果在急性髓系白血病初治组患者,化疗结束后5~7 d FL浓度明显大于化疗前,且明显大于对照组FL浓度([392±55.07)pg/mL,P<0.05]。在缓解组中,3个阶段的浓度差异无统计学意义(P<0.05),但明显低于对照组FL浓度(P<0.05)。并且根据直线相关分析,FL浓度与外周血白细胞数量呈明显负相关(r=-0.464,P<0.05)。结论在急性髓系白血病化疗后,FL浓度与外周血白细胞总数有一定相关性。FL浓度一定程度上反映了患者的骨髓代偿能力。
出处 《广东医学》 CAS CSCD 北大核心 2012年第17期2639-2640,共2页 Guangdong Medical Journal
  • 相关文献

参考文献11

  • 1张之南,沈悌.白血病诊断及治疗标准[M].2版.北京:北京科技出版社,1998:219-229.
  • 2SAVVIDES S N, BOONE T, ANDREW K. Flt3 ligand structure and unexpected commonalities of helical bundless and cystine knots [J]. Nat Stmct Biol, 2000, 7(6) : 486 -491.
  • 3MARASKOVSKY E, DARO E, ROUX E, et al. In vivo genera- tion of human dendritic ceils subsets by Flt3 ligand [ J ]. Blood, 2000, 96(3) : 878 -884.
  • 4MCKENNA H J. Role of hematopoietic growth factors/fit3 ligand in expansion and regulation of dendritic cells [ J ]. Curr Opin He- matol, 2001, 8(3) : 149 -154.
  • 5CURTI A, FOGLI M, RATI'A M, et al. Stem cell factor and FLT3 - ligand are strictly required to sustain the long - term ex- pansion of primitive CD34 DR - dendritic cell precursors[ J]. J Immunol, 2001, 166(2) : 848 -854.
  • 6GAMMA1TONI L, BRUNO S, SANAVIO F, et al. Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoi- eric reconstitution[ J ]. Exp Hematol, 2003, 31 (3) : 261 - 270.
  • 7KAUSHANSKY K. Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic stem cell[ J ]. Ann N Y Aead Sci, 2003, 996:39 -43.
  • 8NAOE T, KIYOI H. Normal and oncogenic FLT3 [ J ]. Cell Mol Life Sci, 2004, 61 (23) : 2932 - 2948.
  • 9WODNAR FILIPOWICZ A, LYMAN S D, GRATWOHL A, et al. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy - induced bone marrow aplasia [ J]. Blood, 1996, 88 (12) : 4493 - 4499.
  • 10CHKLOVSKAIA E, JANSEN W, NISSEN C, et al. Mechanism of fit3 gene ligand expression in bone marrow failure: translocation from intracellular stores to the surface of lymphocytes after chemo- therapy induced suppression of hematopoiesis [ J ]. Blood, 1999, 93 (8) : 2595 - 2604.

二级参考文献22

  • 1Li K, Yang M, Lam AC,et al. Effects of flt-3 ligand in combination with TPO on the expansion of megakaryocytic progenitors, 2000,9(1) : 125-131.
  • 2Robinson S, Mosley RL, Parajuli P, et al. Comparison of the hematopoietic activity of flt-3 ligand and granulocyte-macropbage colony-stimulating factor acting alone or in combination. J Hematother Stem Cell Res,2000,9(5):711-720.
  • 3Blumenthal RD, Walter L, Malik J, et al. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer, 2000,88(2) :333-343.
  • 4Gazitt Y, Liu Q, High steady-state plasma levels of flt3-ligand in the peripheral blood is a good predictor for poor mobilization of CD34 + PBSC in patients undergoing high-dose chemotherapy and stem cell rescue. J Hematother Stem Cell Res, 2000,9 (2) : 285-293.
  • 5Lyman SD,James L, Bos TV, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell,1993,75(6): 1157-1167.
  • 6Lyman SD,James L,Johnson L,et al. Cloning of the human homologue of the murine fit3 ligand: a growth factor for early hematopoietic progenitor cells. Blood, 1994,83(10) : 2795-2801.
  • 7Slanieka Krieger M, Nissen C, Manz CY, et al. The membranebound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietie cells in long-term cultures of normal and aplastie anemia bone marrow. Exp Hematol, 1998,26 (5):365-373.
  • 8Drexler HG,Quentmeier H. FLT3; receptor and ligand. Growth Factors. 2004, 22(2) : 71-73.
  • 9Savvides SN, Boone T, Andrew Karplus P. Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots. Nat Struct Biol. 2000;7(6) :486-491.
  • 10Papayannopoulou T, Nakarnoto B, Andrews RG, et al. In vivo effects of Flt3/Flk2 ligand on mobilization of hernatopoietic progenitors in primates and potent synergistic enhancement with granulocyte colonystimulating factor. Blood, 1997,90(2):620-629.

共引文献2

同被引文献54

  • 1黄耘,王思力,于永洋,樊亚群.去甲氧柔红霉素与柔红霉素治疗老年髓系白血病疗效对比[J].中华临床医师杂志(电子版),2011,5(17):5110-5112. 被引量:8
  • 2Zheng R, Levis M, Piloto O, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood, 2004, 103 : 267-274.
  • 3Maraskovsky E, Daro E, Roux E, et al. In vivo genera- tion of human dendritic cells subsets by Flt3 ligand. Blood, 2000, 96 : 878-884.
  • 4Mckenna HJ. Role of hematopoietic ligand in expansion Curr Opin Hematol, and regulation growth factors/rid of dendritic cells. 2001, 8:149-54.
  • 5Curti A, Fogli M, Ratta M, et al. Stem cell factor and FLT3-1igand are strictly required to sustain the long-term expansion of primitive CD34^+ DR- dendritic cell precur- sors. J Immunol, 2001, 166: 848-854.
  • 6Gammaitoni L, Bruno S, Sanavio F, et al. Ex vivo ex- pansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution. Exp Hematol, 2003, 31: 261-270.
  • 7Kaushansky K. Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic stem cell. Ann N Y Acad Sci, 2003, 996: 39-43.
  • 8Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci, 2004, 61: 2932-2948.
  • 9Woiciechowsky A, Regn S, Kolb HJ, et al. Leukemic dendritic cells generatad in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia- specific cytotoxic T cell response from patients with a- cute myeloid leukemia. Leukemia, 2001, 15: 246- 255.
  • 10Panoskaltsis N, Belanger TJ, Liesveld J, et al. Opti- mal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short- term clture. Leukemia Research, 2002, 26:191-201.

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部